LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference
03/23/2022 - 04:30 PM
LEXINGTON, Mass. , March 23, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau , will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference. The presentation will be available on demand beginning at 7:00 a.m. ET on March 30, 2022 .
A webcast of the presentation will be made available on the Investors section of the Company's website at https://investor.logicbio.com . The webcast replay will be available for approximately 30 days.
About LogicBio® Therapeutics
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit www.logicbio.com , which does not form a part of this release.
Investor Contacts : Stephen Jasper Gilmartin Group 858-525-2047stephen@gilmartinir.com
Media Contacts: Adam Daley Berry & Company Public Relations W:212-253-8881 C: 614-580-2048adaley@berrypr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-at-hc-wainwright-gene-therapy-and-gene-editing-conference-301509368.html
SOURCE LogicBio Therapeutics
LogicBio Therapeutics Inc
LOGC Rankings
N/A Ranked by Stock Gains
LOGC Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Lexington
About LOGC
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA.